10.11.2025: Leadership transition at Cellmover: Miriam Aarsund Larsen appointed as new CEO
Cellmover is pleased to announce that Miriam Aarsund Larsen, previously Chief Scientific Officer, has been appointed as the company’s new Chief Executive Officer.
Former CEO Marit Inngjerdingen will continue to play an active role in the company as Chairman of the Board.
Over the past two years, Miriam has been a driving force in shaping Cellmover’s start-up journey and scientific strategy. Her leadership has been instrumental in advancing the company’s mission to develop next-generation nanobody-based therapies for cancer treatment.
This leadership transition marks an exciting new chapter for Cellmover as the company continues to grow and strengthen its mission of transforming cancer immunotherapy.
01.11.2025: Meet Eline - our new associate scientist
👋 Welcome to the team, Eline Scheie-Ahlgren!
We’re thrilled to have Eline join Cellmover as our new Associate Scientist.
Eline holds a Master’s degree in molecular biology and biochemistry from the University of Oslo, where she tested inhibitors of tumor-promoting factors in pancreatic cancer💊 She recently returned from Paris, where she participated in the international iGEM competition🏆
Eline will be instrumental in driving our nanobody production projects forward — we’re so excited to have her on board!
01.10.2025: Cellmover joins Aleap Incubator
Cellmover is excited to announce that we have joined Aleap, Norway’s leading incubator for health and life science start-ups, located at Oslo Science Park.
Aleap provides an inspiring environment for early-stage companies within biotech, medtech, and health innovation. The incubator offers access to a powerful network of industry experts, experienced mentors, and investors — all dedicated to helping life science ventures scale successfully.
By becoming part of the Aleap community, Cellmover gains access to valuable resources and partnerships that will strengthen our business strategy and accelerate our path toward clinical impact. Aleap’s extensive partner network will provide strategic guidance and expertise across regulatory, intellectual property, business development, and clinical operations.
Becoming part of Aleap marks an important milestone in Cellmover’s growth journey — strengthening our ability to translate groundbreaking science into real-world therapeutic solutions.
01.04.2025: Meet Tirill Marie - our new lab engineer
Say hello to Tirill Marie Trøften, our new Lab Engineer at Cellmover! 👋
Tirill Marie holds a master’s degree in biomedical science and brings valuable experience from working in a GMP-regulated lab. With a strong passion for quality and efficiency, she is dedicated to ensuring that everything in the lab runs smoothly. At Cellmover she will play a key role in delivering reliable and accurate results.
Welcome to the Cellmover team, Tirill Marie! We're excited to have you on board🎉
08.03.2025: Norway’s 50 leading women in tech 2025
Our own CSO Miriam Aarsund Larsen was awarded as one of Norway's leading women in tech 2025! ⭐️⭐️
Today Abelia and ODA-Nettverk released the list of Norway's 50 leading women in tech, with the aim to inspire other women and girls to chose technology as education and career path.
Miriam came to Cellmover full-time in 2024, and has already been key to transform the company to a results-oriented and fast pacing company, aiming to develop next-generation therapeutics for cancer therapy. Miriam is extremely dedicated, hard-working, ambitious, and creative, and sets high standards for herself and the company. Plus you are a wonderful colleague, and a joy to work with.
We are extremely proud today, and also congratulate all other women awarded today with this achievement! 🎉
See the full list here
20.12.2024: Press release alert
01.08.2024: Meet Fredrik - our new senior scientist
Our new addition to the team is Fredrik Gullaksen Johannessen!
Fredrik holds a PhD from the University of Bergen working on proteins related to dopamine synthesis and storage. He has experience from industry as he worked as a scientist in CardiNor AS, focusing on developing diagnostic tests for heart failure biomarkers. Fredrik is responsible for the nanobody- and protein purification pipeline and we are very happy to have him on the team!
